NO912151L - Essensiell-fettsyre-behandling. - Google Patents

Essensiell-fettsyre-behandling.

Info

Publication number
NO912151L
NO912151L NO91912151A NO912151A NO912151L NO 912151 L NO912151 L NO 912151L NO 91912151 A NO91912151 A NO 91912151A NO 912151 A NO912151 A NO 912151A NO 912151 L NO912151 L NO 912151L
Authority
NO
Norway
Prior art keywords
fatty acid
acid treatment
essential fatty
acid
delta
Prior art date
Application number
NO91912151A
Other languages
English (en)
Other versions
NO912151D0 (no
Inventor
David Frederick Horrobin
Michael J Finnen
Original Assignee
Efamol Holdings
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Efamol Holdings filed Critical Efamol Holdings
Publication of NO912151D0 publication Critical patent/NO912151D0/no
Publication of NO912151L publication Critical patent/NO912151L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Fremgangsmåte for fremstilling av et medikament for inhi-bering av fosfolipase A2 ved bekjempelse av inflammasjon, hvor delta-6,9,12,15-oktadekatetraensyre (stearidonsyre) og/eller delta-8,11,14,17-eikosatetraensyre presenteres som medikamentet alene eller i et farmasøytisk tilfredsstillende fortynningsmid-del eller bærer.
NO91912151A 1990-06-06 1991-06-05 Essensiell-fettsyre-behandling. NO912151L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909012651A GB9012651D0 (en) 1990-06-06 1990-06-06 Essential fatty acid treatment

Publications (2)

Publication Number Publication Date
NO912151D0 NO912151D0 (no) 1991-06-05
NO912151L true NO912151L (no) 1991-12-09

Family

ID=10677179

Family Applications (1)

Application Number Title Priority Date Filing Date
NO91912151A NO912151L (no) 1990-06-06 1991-06-05 Essensiell-fettsyre-behandling.

Country Status (12)

Country Link
US (1) US5178873A (no)
EP (1) EP0460848A1 (no)
JP (1) JPH04342525A (no)
KR (1) KR920000324A (no)
AU (1) AU641501B2 (no)
CA (1) CA2043137A1 (no)
FI (1) FI912703A (no)
GB (1) GB9012651D0 (no)
IE (1) IE911741A1 (no)
NO (1) NO912151L (no)
NZ (1) NZ238260A (no)
ZA (1) ZA914001B (no)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2138987T3 (es) * 1993-08-20 2000-02-01 Nestle Sa Composicion lipidica para uso alimenticio.
US5767156A (en) * 1993-10-06 1998-06-16 Peptide Technology Limited Polyunsaturated fatty acids and uses thereof
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5456912A (en) * 1993-12-28 1995-10-10 The Regents Of The University Of California Non-methylene interrupted fatty acids as immunomodulators
GB9403857D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
EP0928185B1 (en) * 1996-06-03 2003-09-03 CRODA INTERNATIONAL plc Compositions and uses thereof
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6107334A (en) * 1998-02-23 2000-08-22 Wake Forest University Dietary control of arachidonic acid metabolism
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
MXPA03010467A (es) * 2001-05-14 2004-12-06 Martek Biosciences Boulder Corp Produccion y uso de una fraccion polar rica en lipidos que contienen acido estearidonico y acido gama-linolenico proviniente de semillas y microbios.
AU2002309931A1 (en) * 2001-05-17 2002-11-25 Pilot Therapeutics, Inc. Method for enriching tissues in long chain polyunsaturated fatty acids
CA2478245A1 (en) * 2002-03-08 2003-09-18 Monsanto Technology Llc Treatment and prevention of inflammatory disorders
AU2002951913A0 (en) * 2002-10-08 2002-10-24 Chevis Agriservices & Consulting Pty. Limited Method of treatment
US7579002B2 (en) * 2003-12-05 2009-08-25 Wisconsin Alumni Research Foundation Method for improving body weight uniformity and increasing carcass yield in animals
JP5207341B2 (ja) * 2006-10-26 2013-06-12 独立行政法人産業技術総合研究所 炎症性サイトカイン産生抑制剤
US7883499B2 (en) * 2007-03-09 2011-02-08 Icu Medical, Inc. Vial adaptors and vials for regulating pressure
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
US20100010088A1 (en) * 2007-11-01 2010-01-14 Wake Forest University School Of Medicine Compositions and Methods for Prevention and Treatment of Mammalian Diseases
WO2009099886A1 (en) * 2008-01-31 2009-08-13 Monsanto Technology Llc Methods of improving dha deposition and related function and/or development
EP2334295B1 (en) 2008-09-02 2017-06-28 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same
GB0902040D0 (en) 2009-02-06 2009-03-11 Seeds Lp Composition for treatment of skin
AU2010213899B2 (en) 2009-02-10 2014-02-06 Amarin Pharmaceuticals Ireland Limited Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
PT3278665T (pt) 2009-04-29 2020-11-19 Amarin Pharmaceuticals Ie Ltd Composição farmacêutica estável e métodos de utilização das mesmas
US11033523B2 (en) 2009-04-29 2021-06-15 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
SG10201708952TA (en) 2009-06-15 2017-12-28 Ian Osterloh Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
US20110071176A1 (en) 2009-09-23 2011-03-24 Amarin Pharma, Inc. Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
SG183883A1 (en) * 2010-03-04 2012-10-30 Amarin Pharma Inc Compositions and methods for treating and/or preventing cardiovascular disease
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
EP2646013A4 (en) 2010-11-29 2014-03-26 Amarin Pharma Inc COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
AU2013207368A1 (en) 2012-01-06 2014-07-24 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject
LT3363433T (lt) 2012-06-29 2021-02-25 Amarin Pharmaceuticals Ireland Limited Širdies ir kraujagyslių sistemos sutrikimų rizikos sumažinimo būdas subjektui, gydomam statinais, panaudojant eikozapentaeno rūgšties etilo esterį
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
WO2015195662A1 (en) 2014-06-16 2015-12-23 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
WO2018213663A1 (en) 2017-05-19 2018-11-22 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject having reduced kidney function
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
SG11202102872QA (en) 2018-09-24 2021-04-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of cardiovascular events in a subject
WO2022225896A1 (en) 2021-04-21 2022-10-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing the risk of heart failure

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4386072A (en) * 1981-06-26 1983-05-31 Horrobin David F Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
JPS5973516A (ja) * 1982-10-21 1984-04-25 Eisai Co Ltd 抗炎症剤
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
US4584320A (en) * 1985-01-03 1986-04-22 David Rubin Anti-asthmatic composition and method using 8,11,14,17-eicosatetraenoic acid
GB8506027D0 (en) * 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
FR2581310B1 (fr) * 1985-05-02 1988-09-23 Natura Medica Laboratoires Composition therapeutique comportant de l'acide a-linolenique et un compose susceptible de favoriser le passage de l'acide au travers de la membrane cellulaire et extrait de plantes comprenant l'acide et le compose
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8621816D0 (en) * 1986-09-10 1986-10-15 Efamol Ltd Therapeutic composition
GB8710780D0 (en) * 1987-05-07 1987-06-10 Scras Opthalmological application of eicosapentaenoic acid
US5225441A (en) * 1987-06-18 1993-07-06 Block Drug Company, Inc. Treatment of periodontal disease
US4843095A (en) * 1987-08-07 1989-06-27 Century Laboratories, Inc. Free fatty acids for treatment or propyhlaxis of rheumatoid arthritis arthritis
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Also Published As

Publication number Publication date
FI912703A0 (fi) 1991-06-05
KR920000324A (ko) 1992-01-29
AU7734391A (en) 1991-12-12
AU641501B2 (en) 1993-09-23
JPH04342525A (ja) 1992-11-30
US5178873A (en) 1993-01-12
CA2043137A1 (en) 1991-12-07
NO912151D0 (no) 1991-06-05
EP0460848A1 (en) 1991-12-11
GB9012651D0 (en) 1990-07-25
FI912703A (fi) 1991-12-07
IE911741A1 (en) 1991-12-18
NZ238260A (en) 1997-07-27
ZA914001B (en) 1992-03-25

Similar Documents

Publication Publication Date Title
NO912151L (no) Essensiell-fettsyre-behandling.
GEP20022656B (en) 2-(Purin-9-YL)-Tetrahydrofuran-3,4-Diol Derivatives
ZA937148B (en) Dioic acids.
NO994256D0 (no) SmÕ molekyler som er anvendelige ved behandling av inflamasjonssykdom
AU3432989A (en) Product and method for the treatment of acne etc.
AU7943491A (en) Essential fatty acid compositions
DK0654264T3 (da) Anvendelse af venlafaxin eller en aryloxypropanaminforbindelse til fremstilling af et lægemiddel til behandling af urininkontinens
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
ES488120A1 (es) Procedimiento para la preparacion de corticoide-17-alcohil- carbonatos
AU5471190A (en) Method of topically treating acne vulgaris
HU913776D0 (en) Process for the production of heparosane-n,o-sulphates, and medical preparations containing them as active agents
AU4445089A (en) Lactamimides in the treatment of drug-resistant protozoal infections
AU2861389A (en) Disubstituted pyridines
HUT57178A (en) Process for producing new retinoids and paharmaceutical compositions comprising such active ingredient
AU641279B2 (en) Oligosaccharide derivatives
AU569102B2 (en) Monohydroxy-benzoyl peroxide
HUT61199A (en) Process for producing pharmaceutical compositions suitable for treating hyperlipidaemia and/or atherosclerosis
IE830664L (en) Treating acne
ES2159294T3 (es) Metodo y composicion para el tratamiento de la caida del cabello.
GEP20012511B (en) Method for Lowering Level of Lipoproteins (a) in Serum or Plasma of Mammals, Method for Treatment of Peripheral Vascular Diseases or Restenosis
IE870577L (en) Topical amide preparation
UA43337C2 (uk) Гормональний засіб для лікування вугрів
FR2690152B1 (fr) Procede de preparation et de traitement de propulseurs.
GR3025064T3 (en) New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardio-vascular system, processes for their preparation and pharmaceutical compositions containing same